How to Cite
Abstract
Malignant glioma is the most frequently occurring primary brain tumor. Despite significant progress in the diagnostics and treatment of neoplastic diseases the prognosis for patients with III-IV grade gliomas, remains extremely unfavorable. Rapidly developing area in oncology is the employment of therapeutic viruses with natural or genetically engineered oncolytic activity. In the present study we demonstrated the oncolytic potential of a recombinant influenza A virus vector with impaired interferon antagonism function of NS1 protein in treatment of malignant glioma. Recombinant influenza A virus (HA-DS-GFP) expressing green fluorescent protein from the NS1 open reading frame was used as a model vector. HA-DS-GFP virus has shown infectivity towards glioma cells both in vitro, and in vivo (experimental glioma model in rats). Intratumoral inoculation of HA-DS-GFP resulted in a substantial inhibition or complete regression of tumor growth. Our data demonstrate that recombinant influenza vectors have promising potential in therapy of malignant gliomas.References
CBTRUS. Statistical report: Primary Brain Tumors in the United States, 1998. - 2002. - 2005 - P. 202.-224.
Adams H., Chaichana K. L., Avendano J. et al. Adult cerebellar glioblastoma: understanding survival and prognostic factors using a population-based database from 1973 to 2009 // World Neurosurg. - 2013. - Vol. 80 (6). - P. 237-243.
Agarwalla P.K., Barnard Z.R., Curry W.T. Jr. Virally mediated immunotherapy for brain tumors // Neurosurg. Clin. N. Amer. - 2010. - Vol. 21. - P. 167-179.
Barzon L., Pacenti M., Franchin E. et al. HSV-TK/IL-2 gene therapy for glioblastoma multiforme // Methods Mol. Biol. - 2009. - Vol. 4. - P. 529-549.
Bergmann M., Garcia-Sastre A., Carnero E. et al. Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication // J. Virol. - 2000. - Vol. 74. -P. 6203-6206.
Bergmann M., Romirer I., Sachet M. et al. A genetically engineered influenza A virus with ras-dependent oncolytic properties // Cancer Res. - 2001. - Vol. 61. - P. 8188-8193.
Chargari C., Moncharmont C., Levy A. et al. Cancer stem cells, cornerstone of radioresistance and perspectives for radiosensitization: glioblastoma as an example // Bull. Cancer. - 2012. - Vol. 99 (12) - P. 1153-1160.
Colombo F., Barzon L., Franchin E., Pacenti M. et al.Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results // Cancer Gene Ther. - 2005. - Vol. 12. - P. 835-848.
Dey M., Auffinger B., Lesniak M. S. et al. Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making? // Future virology 2013. - Vol. 8. - P. 675693.
Efferson C.L., Tsuda N., Kawano K. et al. Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells // J. Virol. - 2006. - Vol. 80. -P. 383-394.
Ferko B., Stasakova J., Sereinig S. et al. Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type1 Nef-specific systemic and mucosal immune responses in mice // Ibid. - 2001. - Vol. 75. -P 8899-8908.
Fujiwara T. In vivo imaging of human cancer with telomerase-specific replication-selective adenovirus // Methods in molecular biology. - 2012. - Vol. 872. - P. 129-139.
Garcfa-Sastre A., Percy N., Barclay W., Palese P Introduction of foreign sequences into the genome of influenza A virus // Dev. Biol. Stand. - 1994. - Vol. 82. - P 237-246.
Garcfa-Sastre A., Egorov A., Matassov D., Brandt S. et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems // Virology. - 1998. - Vol. 252. -P. 324-330.
Hatada E., Saito S., Fukuda R. Mutant influenza viruses with a defective NS1 protein cannot block the activation of PKR in infected cells // J. Virol. - 1999. - Vol. 73. - P 2425-2433.
Hoffmann E. and Webster R. G. Unidirectional RNA polymerase I-polymerase IItranscription system for the gen eration of influenza A virus from eight plasmids // J Gen Virol. - 2000. - Vol. 81 (Pt 12). - P. 2843-2847.
Huang P.I., Chang J.F., Kirn D.H., Liu T.C. Targeted genetic and viral therapy for advanced head and neck cancers // Drug Discov. Today. - 2009. - Vol. (11-12). - P 570-578.
Kittel C., Ferko B., Kurz M. et al. Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment // J. Virol. - 2005. - Vol. 79. - P 10672 -10677.
Kuznetsova I., Shurygina A.-P, Wolf B. et al. Adaptive mutation in nuclear export protein allows stable transgene expression in a chimaeric influenza A virus vector // J. Gen. Virol. - 2005. - Vol. 95 (Pt 2). - P 337-349.
Kyritsis A.P, Sioka C., Rao J.S. Viruses, gene therapy and stem cells for the treatment of human glioma // Cancer Gene Ther. - 2009. - Vol. 16. - P 741 -752.
Mineta T., Rabkin S. D., Yazaki T. et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas // Nat. Med. - 1995. - Vol. 1 (9). - P 938-943.
Muster T., Rajtarova J., Sachet M., Unger H.et al. Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants // Int. J. Cancer. - 2004. - Vol. 110 (1) - P. 15-21.
Nabors, L. B., M. Ammirati, Bierman, P J. et al. Central nervous system cancers // J Natl Compr. Canc. Netw. - 2013. - Vol. 11 (9). - P 1114-1151.
Ning J. and Wakimoto H. Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy // Frontiers in microbiology. - 2014. - Vol. 5. - P. 303.
Palù G., Cavaggioni A., Calvi P et al. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans // Gene Ther. - 1999. - Vol. 6. - P. 330 -337.
Pleschka, S., R. Jaskunas, Engelhardt O.G. et al. A plasmid-based reverse genetics system for influenza A virus // J Virol. - 1996. - Vol. 70 (6). - P. 4188-4192.
van Rikxoort M., Michaelis M., Wolschek M. et al. Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame // PloS one. - 2012. - Vol. 7. -P.e. 36506.
Sereinig S., Stukova M., Zabolotnyh N. et al. Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge // Clin. Vaccine Immunol. - 2006. - Vol. 13. - P. 898 -904.
Tobias A. L., Thaci B., Auffinger B., et al. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma // Stem Cells Transl. Med. - 2006. - Vol. 2 (9). - P 655-666.
Shi J., Zheng D. An update on gene therapy in China // Curr. Opin. Mol. Ther. - 2009. - Vol. 11. - P. 547 -553.
Wacheck V., A. Egorov. Groiss F. et al. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1 // J. Infect. Dis. - 2010. -Vol. 201(3). - P 354-362.
Weiss R., Sachet M., Zinngrebe J. et al. IL-24 sensitizes tumor cells to TLR3-mediated apoptosis // Cell death and differentiation. - 2013. - Vol. 20. - P -833.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...